Gemigliptin/metformin

Drug Profile

Gemigliptin/metformin

Alternative Names: FDC (gemigliptin/metformin HCl sustained release) - LG Life Sciences; Metformin/gemigliptin; ZemiMet SR

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem
  • Class Antihyperglycaemics; Biguanides; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Aug 2015 LG Life Sciences initiates a phase I trial in Healthy male volunteers in South Korea (NCT02670018)
  • 02 Feb 2015 LG Life Sciences completes a phase I trial in Healthy volunteers in South Korea (NCT01595880)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top